2,6-difluoro-4-(N,N-dibenzylamino)benzaldehyde | 226411-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-difluoro-4-(N,N-dibenzylamino)benzaldehyde
• 英文别名: 4-(dibenzylamino)-2,6-difluorobenzaldehyde
• CAS: 226411-01-4
• 化学式: C₂₁H₁₇F₂NO
• 分子量: 337.369
• InChiKey: SXYKNPSHHPWNMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,6-difluoro-4-(N,N-dibenzylamino)benzaldehyde 在 lithium aluminium tetrahydride 、 ammonium acetate 作用下， 以 乙醚 为溶剂， 反应 9.0h， 生成 [4-(2-Amino-propyl)-3,5-difluoro-phenyl]-dibenzyl-amine
  参考文献：
  名称：

  Prodrugs of neuron-selective monoamine oxidase inhibitors: amino acid derivatives of 1-(4-aminophenyl)-2-aminopropanes

  摘要：

  Six amino acid derivatives of 1-(4-aminophenyl)-2-aminopropanes and their parent amines were synthezised and tested for their potency and selectivity in inhibiting monoamine oxidase (MAO) in vitro and in vivo. The amino acid derivatives were 300-1000 times less potent than the parent amines in inhibiting the MAO-A activity in a rat brain mitochondrial preparation in vitro. All compounds, except the (R)-valinamide derivative (22), were potent inhibitors of MAO in the rat brain in vivo and were, like the parent amines markedly more potent within the monoaminergic neurons than in other neurons. The glycinamide derivative 7 showed the largest difference between intra- and extra-neuronal inhibition in serotonergic neurons. The time course of the inhibitory effect of 7 in vivo showed that it is a reversible inhibitor with a long duration. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80047-6
• 作为产物：
  描述：

  3,5-二氟苯胺 在 正丁基锂 、 potassium carbonate 、 potassium iodide 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 2,6-difluoro-4-(N,N-dibenzylamino)benzaldehyde
  参考文献：
  名称：

  Prodrugs of neuron-selective monoamine oxidase inhibitors: amino acid derivatives of 1-(4-aminophenyl)-2-aminopropanes

  摘要：

  Six amino acid derivatives of 1-(4-aminophenyl)-2-aminopropanes and their parent amines were synthezised and tested for their potency and selectivity in inhibiting monoamine oxidase (MAO) in vitro and in vivo. The amino acid derivatives were 300-1000 times less potent than the parent amines in inhibiting the MAO-A activity in a rat brain mitochondrial preparation in vitro. All compounds, except the (R)-valinamide derivative (22), were potent inhibitors of MAO in the rat brain in vivo and were, like the parent amines markedly more potent within the monoaminergic neurons than in other neurons. The glycinamide derivative 7 showed the largest difference between intra- and extra-neuronal inhibition in serotonergic neurons. The time course of the inhibitory effect of 7 in vivo showed that it is a reversible inhibitor with a long duration. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80047-6

文献信息

• Aminophenylpropanoic Acid Derivative
  申请人：Yasuma Tsuneo

  公开号：US20080269220A1

  公开（公告）日：2008-10-30

  A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

  化合物的化学式为（1）：其中每个符号如规范所定义，其盐和前药意外地具有更优越的GPR40受体激动剂活性，在药品产品的稳定性等方面具有优越性，并且可以作为安全有效的药物用于预防或治疗GPR40受体相关的病理或疾病，例如糖尿病等。
• Aminophenylpropanoic acid derivative
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07786165B2

  公开（公告）日：2010-08-31

  A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

  化合物的化学式为(1)：其中每个符号如规范中所定义，其盐和前药意外地具有优越的GPR40受体激动剂活性，具有制药产品的优越性能，例如稳定性等，并且可以作为治疗或预防GPR40受体相关病理或疾病，如糖尿病等的药物而成为安全有效的药物。
• AMINOPHENYLPROPANOIC ACID DERIVATIVE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1726580A1

  公开（公告）日：2006-11-29

  A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

  式 (1) 所代表的化合物： 其中各符号如说明书中所定义，其盐及其原药意外地具有优异的 GPR40 受体激动剂活性、优异的稳定性等药剂特性，可作为预防或治疗 GPR40 受体相关病理或疾病（如糖尿病等）的安全有用的药剂。
• EP1726580
  申请人：——

  公开号：——

  公开（公告）日：——
• US7786165B2
  申请人：——

  公开号：US7786165B2

  公开（公告）日：2010-08-31